2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1739

Kawasaki Disease Shock Syndrome – More Common Than We Think: Our Experience at Chandigarh, North India
Abstract Number: 1740

Orange Brown Chromonychia in Kawasaki Disease: A Clinical Sign That Merits Greater Attention
Abstract Number: 1741

Depression and Anxiety Symptoms in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1742

Ethnicity and Neonatal Lupus Erythematosus Manifestations Risk in a Large Multi-Ethnic Cohort
Abstract Number: 1743

Kawasaki Disease: Is Intravenous Immunoglobulin Alone Adequate for the Child with Kawasaki Disease and Coronary Artery Lesions? A Retrospective Study of 65 Children with Kawasaki Disease from a Single North Indian Centre
Abstract Number: 1744

Serum Sickness Following Rituximab Treatment of Childhood-Onset SLE: A Single Center Experience
Abstract Number: 1745

Exercise Improves Arterial Inflammation in Childhood-onset Takayasu Arteritis: A Randomized Controlled Trial
Abstract Number: 1746

Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers
Abstract Number: 1747

Practice Variations in Treatment of Pediatric Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV) with Renal Disease
Abstract Number: 1748

Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood
Abstract Number: 1749

Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center
Abstract Number: 1750

Pediatric Sjögren Syndrome: A Single-Center Experience
Abstract Number: 1751

A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis
Abstract Number: 1752

Is Early Standardized Rituximab Therapy Sufficient for Toddlers with NMDAR Encephalitis?
Abstract Number: 1753

Are Patterns of Early Disease Severity Predictive of Grade 12 Academic Achievement in Patients with Childhood-onset Chronic Rheumatic Diseases?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].